The correlation between serum anti-tuberculosis (TB) drug levels and the drug-induced hepatotoxicity (DIH) remains unclear. The three key anti-tuberculosis drugs, viz isoniazid, pyrazinamide and rifampicin, are potentially hepatotoxic.1 Deaths due to fulminant liver necrosis have been reported, albeit rare in occurrence.

doi: 10.1371/journal.pone.0236109. 2020 Jul 21;15(7):e0236109. The purpose of this study was to investigate whether anti-TB DIH is associated with basal serum drug levels.

Ten patients showed PZA-related hepatotoxicity and 2 showed INH- or RMP-related hepatotoxicity. Thus the clinical relevance of therapeutic monitoring of serum rifampicin concentrations in managing DIH is still being explored.Present study done to observe serum rifampicin, isoniazid, pyrazinamide level in patients on ATT and to compare it retrospectively between patients who develop drug induced hepatitis vs those who do not.Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs.Subjects: Patients with diagnosis of CatI/CatIII Tuberculosis attending the out-patient department of the All India Institute of Medical Sciences, New Delhi, will form the study population.Cases - those patients who develop DIH while on regular treatment with anti-TB drugs Controls - age, sex matched patients who do not develop DIH while on regular treatment with anti-TB drugs

2020 May 12;2020:9631731. doi: 10.1155/2020/9631731. Serum peak levels of isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), and ethambutol (EMB) were analyzed in blood samples 2 hr after the administration of anti-TB medication.

Patients who have not had any TB treatment before, or they have had less than one month of anti TB drugs, are considered to be new patients. Globally 8.9 million new cases of tuberculosis occur annually, of which 1.8 million (20%) occur in India.Short-course chemotherapy containing isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA) has proved to be highly effective in the treatment of tuberculosis. TB which is not resistant to any of the TB drugs) unless there is a high level of isoniazid resistance in new patients in the area. In most cases hepatitis is evident within three months of start of antituberculosis treatment (ATT). ScienceDirect ® is a registered trademark of Elsevier B.V.Classifying new anti-tuberculosis drugs: rationale and future perspectives© 2016 The Author(s). However, a systematic review should be pursued in order to confirm or strengthen the basis of our call for a revision.How the available evidence should be used for the reclassification process is a crucial issue because there are methodological difficulties in evaluating the effect of a single component of a multidrug regimen. doi: 10.5588/ijtld.13.0128.Verbeeck RK, Günther G, Kibuule D, Hunter C, Rennie TW.Eur J Clin Pharmacol. The latest evidence on the ex-group 5 drugs is also discussed.We use cookies to help provide and enhance our service and tailor content and ads. 1.2 Co-infections, particularly in the developing world Throughout the world, HIV overlaps with other epidemics such as tuberculosis (TB), malaria and chronic viral hepatitis. DR-TB treatment should be aware of the risk of ototoxicity, its early symptoms and signs, diagnosis, and management. eCollection 2020 Jun.Biomed Res Int.

With the changing demographics and clinical characteristics of tuberculosis patients …

The purpose of this study was to investigate whether anti-TB DIH is associated with basal serum drug levels.

Flow diagram showing the progress of study subjects through the study.

When this happens, the regimen becomes even weaker and, once bedaquiline or delamanid are stopped after 6 months, the regimen is prone to failFollowing the proposed reclassification of groups 2 and 3, the injectable SLDs might have the characteristics of a future group 4 (A future hypothetical group 5 should include the thionamides (ethionamide or prothionamide) that currently belong to group 4, of which they represent the best drugs: the only ones with some bactericidal activity [A new revised Group 5 might therefore include other SLDs that, although not very powerful, can offer support in the treatment regimens (This hypothetical proposal may have some important implications. The aim of this viewpoint article is to describe the evolution in WHO TB classification (taking into account an independently proposed new classification) and recent changes in WHO guidance, while commenting on the differences between them.

COVID-19 is an emerging, rapidly evolving situation. The core difficulty in evaluating the role and contribution of a single drug is represented by the fact that DST-tailored regimens are put together as a cocktail of different drugs; however, this difficulty is the same faced some years ago, when the potential role of each anti-TB drug was evaluated in order to build the current recommendations for MDR-TB management. The authors have no potential conflicts of interest to disclose. A total of 195 TB patients were included in the study, and the data were analyzed retrospectively.

2016 Aug;72(8):905-16. doi: 10.1007/s00228-016-2083-4.